Canopy Growth (CGC) shares have been in a sharp uptrend this week following reports President Donald Trump will reclassify cannabis as a “Schedule III” drug within the next few days. Additionally, the president is also considering announcing a Medicare pilot program that would let some seniors access cannabis products at a subsidized rate. More News from Barchart At the time of writing, CGC shares are up a remarkable 90% versus their low in late November. www.barchart.com Is Canopy Growth Stock Worth ...